



Media release

## **evismo closes CHF 1 million financing round for scale up**

**Swiss eHealth startup evismo raises CHF 1 million in its seed round. Zühlke Ventures AG joins evismo together with various business angels. The additional capital will be used to scale evismo's innovative business model, 'Diagnostics-as-a-Service' for patients and doctors.**

*Zurich, September 14, 2021 - evismo announces the successful completion of its seed round. Founded in February 2018, evismo develops and connects new technologies in healthcare with the goal of providing patients with optimal care in prevention, diagnosis and therapy via remote monitoring. evismo offers 'Diagnostics-as-a-Service' to physicians, cardiologists and hospitals. Its first product, the long-term ECG CardioFlex®, is used for cardiac diagnostics for patients with suspected cardiac arrhythmias. It is already in use at over 50 doctors' practices and clinics in Switzerland. evismo has thus far analyzed over 400,000 hours from more than 3,000 patients.*

### **Zühlke Ventures AG as lead investor sees strong growth**

The venture arm of Zühlke Engineering and various business angels, including members of the Swiss Health Angels and Business Angels Switzerland, participated in the oversubscribed seed financing round. Patrick Griss of Zühlke Ventures: *« As active investor in Swiss and international HealthTech start-ups, we closely follow the dynamics in the healthcare market. evismo clearly differentiates itself with its innovative product CardioFlex® and an attractive business model of diagnostics as a service. Accordingly, the company's growth is already impressive at this early stage. We are proud to accompany evismo on their journey to become a global 'Diagnostics-as-a-Service' provider. »*

Jochen Ganz, entrepreneur and investor, and Tero Pasanen, Sales Director Bittium, are new members of the evismo AG Board of Directors.

### **Expanded product portfolio and build-up of the 'Diagnostics-as-a-Service' platform**

The funding will be used to scale the existing CardioFlex® product in the Swiss market and establish it as the gold standard for long-term ECG diagnostics. At the same time, other products for measuring vital signs are in the pipeline for launch. Willemien van den Toorn, Co-Founder of evismo: *«Market needs and requirements are clear. We will use the additional funding to make our diagnostic services even more widely known and bring additional products*



and services to market.» For the planned growth in Switzerland, evismo is looking to expand its sales team with reps who are well-connected amongst the medical community.

To link the various products into a complete 'Diagnostics-as-a-Service' offering for patients and physicians, evismo is developing its software platform as a central hub. For this purpose, evismo is looking for versatile software developers.

#### About [evismo](#)

evismo is driven by the belief that every patient deserves a diagnosis. Our goal is to provide a diagnostic solution that captures the previously unmeasured. To achieve this, evismo brings medical care directly into the everyday lives of patients, in a cost-efficient and patient-centric way. evismo rethinks existing, outdated, complex systems and intelligently connects the relevant players. evismo makes professional remote monitoring available to optimise diagnostics, prevention, therapy and treatment outcomes.

#### Media contact

Willemien van den Toorn

Co-Founder

+41 79 675 58 53

[wvandentoorn@evismo.com](mailto:wvandentoorn@evismo.com)



Co-Founder Alexander Panos & Willemien van den Toorn